Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company dedicated to overcoming cancer drug resistance, announced that CEO and Chairman John Yu, MD, will deliver a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026, at the Lotte New York Palace Hotel. This presentation marks a key opportunity for the company to communicate its strategic vision and clinical advancements to the investment community.
The significance of this event lies in Kairos Pharma's innovative approach to oncology. Unlike traditional therapies that directly attack cancer cells, Kairos Pharma leverages structural biology to address the underlying mechanisms of drug resistance and immune suppression—two major barriers to effective cancer treatment. Its lead candidate, ENV-105, is a monoclonal antibody targeting CD105, a protein identified as a pivotal driver of resistance and disease relapse following standard therapy. By neutralizing CD105, ENV-105 aims to resensitize tumors to existing treatments, potentially extending their efficacy across multiple cancer types.
This strategy holds substantial implications for patients and the healthcare system. Drug resistance is a leading cause of cancer treatment failure, often leading to disease progression despite aggressive therapy. If ENV-105 succeeds in clinical trials, it could offer a new option for patients who have exhausted current therapies, potentially improving outcomes and quality of life. Moreover, by restoring the effectiveness of standard chemotherapies and immunotherapies, ENV-105 could reduce the need for costly and toxic alternative treatments, alleviating the economic burden on patients and payers.
The conference presentation will allow Kairos Pharma to showcase its pipeline and clinical data to a broad audience of institutional investors, analysts, and industry stakeholders. Such visibility is crucial for a clinical-stage company seeking to secure funding for ongoing trials and future development. The company's participation in this prestigious event, organized by H.C. Wainwright & Co., a leading investment bank specializing in healthcare, signals growing interest in its novel therapeutic approach.
Kairos Pharma is based in Los Angeles, California, and is at the forefront of oncology therapeutics, focusing on structural biology to overcome drug resistance. The company's commitment to addressing these challenges is reflected in its scientific leadership and strategic collaborations. As it advances ENV-105 through the clinical pipeline, the outcomes of its trials will be closely watched by the medical and investment communities alike.
Investors and stakeholders can access the latest news and updates regarding Kairos Pharma through the company's newsroom at https://ibn.fm/KAPA. The full press release detailing this announcement is available at https://ibn.fm/NrBQD.
The upcoming H.C. Wainwright conference will feature presentations from numerous public and private companies in the healthcare sector, providing a platform for networking and knowledge exchange. Kairos Pharma's participation underscores its commitment to advancing cancer care and creating value for shareholders. With ENV-105's potential to address a critical unmet need, the company's presentation is poised to generate significant interest and highlight its role in shaping the future of oncology treatment.
